|1.||Serhan, Charles N: 2 articles (06/2014 - 01/2009)|
|2.||Sadovnikov, V B: 2 articles (01/2011 - 07/2009)|
|3.||Navolotskaia, E V: 2 articles (01/2011 - 07/2009)|
|4.||Zhang, Tian: 1 article (06/2015)|
|5.||Qu, Wen: 1 article (06/2015)|
|6.||Guan, Jing: 1 article (06/2015)|
|7.||Song, Jia: 1 article (06/2015)|
|8.||Meng, Yinping: 1 article (06/2015)|
|9.||Fu, Rong: 1 article (06/2015)|
|10.||Ding, Shaoxue: 1 article (06/2015)|
04/01/1993 - "These DAF- and CD59/MACIF-deficient erythrocytes disappeared almost completely with progression of the leukemia. "
02/01/2001 - "Because complete remission of AML was not achieved by intensive chemotherapies, allogeneic peripheral blood stem cell transplantation (PBSCT) from the patient's HLA-matched sister was performed successfully with recovery of CD59 antigen on bone marrow hematopoietic cells; however, leukemia relapsed 4 months after PBSCT. "
04/01/1993 - "The patient's erythrocytes lacking DAF and CD59/MACIF expression corresponded to the proportion of complement-sensitive cells at the onset of acute leukemia. "
01/01/1993 - "The tumor promoting phorbol ester TPA induced a marked up-regulation of protectin in all examined cell lines with the exception of promyelocytic leukemia HL-60, where TPA significantly decreased protectin cell surface expression. "
|2.||Melanoma (Melanoma, Malignant)
05/16/1995 - "Immunohistochemical and/or indirect immunofluorescence analysis with monoclonal antibody (MAb) H19 demonstrated the expression of protectin (CD59) in 54 surgically removed metastatic melanoma lesions and on 8 out of 12 melanoma cell lines. "
03/01/1994 - "In the present study we have developed a procedure to simultaneously direct the complement membrane attack complex and neutralize its inhibitor CD59 (protectin) on human melanoma cells in vitro. "
12/01/2000 - "Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement."
09/01/1997 - "Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity."
05/16/1995 - "Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity."
05/01/1991 - "Using a specific monoclonal antibody, 1F5, against HRF20, we attempted to study the localization of HRF20 in human glomerulonephritides and to compare the localization of HRF20 with those of immune deposits and MAC. "
01/01/2000 - "This study assessed the expression of complement receptor 1 (CR1), decay accelerating factor (DAF) and membrane inhibitor of reactive lysis (CD59) on the erythrocytes and glomerulus of diffuse proliferative glomerulonephritis (DPGN) of systemic lupus erythematosus (SLE) patients using flow cytometry and immunofluorescence techniques to elucidate their role in the pathogenesis of DPGN. "
11/01/1992 - "In the present study we investigated expression of protectin in human heart and examined the relationship between MAC deposition and protectin in myocardial infarction. "
04/01/1997 - "In cases of myocardial infarction of 20 h or less, MAC deposition was shown in the infarcted cardiomyocytes without loss of HRF20. "
11/01/1992 - "Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction."
01/01/2011 - "Peptide CH3CO-Lys-Lys-Arg-Arg-NH2 (protectin) was synthesized and its activity was studied on the model of experimental myocardial infarction in rats in comparison to the reference antihypoxant drug riboxin. "
04/01/1997 - "In order to investigate the mechanism of deposition of the complement membrane attack complex (MAC) in cardiomyocytes in areas of human myocardial infarction, the 20 kDA homologous restriction factor of complement (HRF20; CD59) and complement components (Clq. "
|5.||Skin Neoplasms (Skin Cancer)
|1.||CD55 Antigens (Decay Accelerating Factor)
|2.||Complement Membrane Attack Complex (Membrane Attack Complex)
|4.||Complement Receptors (Complement Receptor)
|6.||Integrin beta3 (GPIIIa)
|8.||Transcription Factors (Transcription Factor)
|9.||Surface Antigens (Surface Antigen)
|10.||Complement System Proteins (Complement)
|1.||Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
|2.||Drug Therapy (Chemotherapy)